The patent cliff for Keytruda is fast approaching in the U.S. Now, as Merck & Co. increasingly looks to life after its oncology megablockbuster, the company is honing its focus on new and upcoming ...

Merck (NYSE:MRK) received FDA approval for KEYTRUDA and its new subcutaneous formulation, KEYTRUDA QLEX, in combination ...

The two blockbusters have made a big difference in bladder cancer survival, but will their chemistry hold up when tested in other types?

Merck said on Monday it would split its business into two, creating ⁠a division for its cancer franchise while grouping its ​non-oncology treatments separately.

Merck (NYSE:MRK) reported a series of positive late stage clinical trial results for oncology and HIV therapies, including ...

The winners will not be those who merely predict cliffs, but those who re-architect early enough. Merck’s oncology spin-out underscores a defining reality of modern pharma: molecules may create value, ...

(Reuters) -Merck & Co on Thursday posted higher third quarter revenue as growth from its blockbuster cancer drug Keytruda offset falling sales from human papillomavirus vaccine Gardasil in China.

A meaningful portion of Merck’s MRK revenues comes from its oncology franchise anchored by its blockbuster PD-L1 inhibitor, Keytruda. The drug contributes over half of the company’s pharmaceutical ...

In late February 2026, Merck reported a wave of positive late-stage data and regulatory milestones for KEYTRUDA-based ...

A combination of Merck’s Keytruda and Pfizer’s Padcev could offer a chemotherapy-free treatment alternative for patients with ...

MRK's Keytruda posted $31.7B in 2025 sales. Can new approvals, ongoing studies and a revamped structure keep oncology growth strong through 2026?

This underscores the US drugmaker’s push to diversify beyond its blockbuster drug Read more at The Business Times.